| ¿µ¹® | cardiotonic, cardiotonic agent | ÇÑ±Û | °½ÉÁ¦ |
|---|---|---|---|
| ¼³¸í | ½ÉÀåÀÇ ¼öÃà·ÂÀ» Áõ°¨½ÃŰ´Â ¾à¹°À» ¸»ÇÑ´Ù. ±âº»ÀûÀ¸·Î ½É±Ù¼öÃà·ÂÀ» Áõ°½ÃÄÑ ½ÉÀå¹ÚÃâ·®À» Áõ°¡½ÃŰ´Â ¾à¹°ÀÌ´Ù. °½É¹è´çü, Æ÷½ºÆ÷µð¿¡½ºÆ®¶ó¾ÆÁ¦ ¾ïÁ¦Á¦, ¾Æµå·¹³¯¸° ¥â¼ö¿ëüÀÛ¿ëÁ¦, Ç÷°üÈ®ÀåÁ¦ µîÀÌ ÀÖ´Ù. ´ëÇ¥ÀûÀÎ ¿¹·Î¼´Â µð°î½Å(digoxine) µîÀÇ µðÁöÅ»¸®½º(digitalis)°¡ ÀÖ´Ù. |
||
| ¿µ¹® | alkylating agent | ÇÑ±Û | ¾ËųȾ๰ |
|---|---|---|---|
| ¼³¸í | Ç×¾ÏÁ¦ÀÇ ÀÏÁ¾. ÀÌ»óÀûÀÎ Ç×¾ÏÁ¦´Â Á¤»óÀûÀÎ ¼¼Æ÷¿¡´Â ÇØ¸¦ ÁÖÁö ¾Ê°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀÎ È¿°ú¸¦ ³ªÅ¸³»¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀÇ Æ¯ÀÌÇÑ Æ¯¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇÏ´Â ¾à¹°À» °³¹ßÇØ¾ß ÇÑ´Ù. ÇöÀç ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº ´Ù½Ã ¸»Çϸé À¯Àü Á¤º¸¸¦ °¡Áö°í ÀÖ´Â DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼µµ Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â Á¤»óÀûÀÎ ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒȰüÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î ÀÌµé ¼¼Æ÷µµ ÇÔ²² Ä¡¸íÀûÀÎ ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒȺҷ®ÀÌ Àß ¿Â´Ù). ¾ËĮȾ๰ÀÇ °æ¿ì¿¡´Â DNA¿Í Á÷Á¢ °áÇÕÀ» ÇÏ¿© DNAÀÇ º¹Á¦¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á Ç×¾ÏÁ¦ÀÇ ¿ªÇÒÀ» ¼öÇàÇÑ´Ù. |
||
| ¿µ¹® | anti-inflammatory agent | ÇÑ±Û | Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à |
|---|---|---|---|
| ¼³¸í | ±¹¼Ò¿¡ ÀÛ¿ëÇÏ¿© ¿°ÁõÀ» Ä¡·áÇÏ°í ¹æÁöÇÏ´Â ¾à. ¿°ÁõÀ» °¡¶ó¾ÉÈ÷´Â ¾àÀ» ¸»ÇÑ´Ù. Á¶Á÷À» ±äÃà-Ä¡¹ÐÇÏ°Ô ÇÏ¿© Àå¾×°ú Á¡¾×ÀÇ ºÐºñ¸¦ ÁÙÀ̰í, Ç¥¸é¿¡ ÀÖ´Â ÀÛÀº Ç÷°ü¿¡ ºóÇ÷À» ÀÏÀ¸ÄÑ ÃæÇ÷µÇ´Â °ÍÀ» ¹æÁöÇÔÀ¸·Î½á ¿°ÁõÀû º´º¯À» Á¦°ÅÇÏ¿© ¸ðµç Áõ¼¼¸¦ ¾ø¾Ø´Ù. ´ëºÎºÐÀÇ ¼ö·ÅÁ¦-¿ÏÈÁ¦-Áø¾çÁ¦°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. Áß¿äÇÑ ¼ººÐÀ¸·Î´Â ¾Ë·ç¹Ì´½-ºñ½º¹«Æ®-¾Æ¿¬-³³ÈÇÕ¹°(º´¹Ý-Æä¸£¸¶Åç-¾Æ¿¬È-¿¬´ç µî) µîÀÌ ÀÖ´Ù. ÀÛ¿ë¿¡ µû¶ó Ç׿°ÁõÁøÅëÁ¦¿Í Ç׿°ÁõÈ¿¼ÒÁ¦·Î ³ª´¶´Ù. |
||
| ¿µ¹® | acute hepatitis | ÇÑ±Û | ±Þ¼º°£¿° |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, ÀÌ´Â ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇÏ´Â ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°ÀÌ¸ç ³ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀÌ Ã£¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³´Ù. µÚÀ̾î Ȳ´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª Ȳ´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â Ȳ´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» ÇØµµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀÌ Æ¯Â¡ÀÌ¸ç ±Þ¼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º¿î °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀÎ °ÍÀÌ º¸ÅëÀÌ´Ù. |
||
| ¿µ¹® | acute appendicitis | ÇÑ±Û | ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿° |
|---|---|---|---|
| ¼³¸í | ¿Ü°úÀû óġ¸¦ ¿äÇÏ´Â ¸·Ã¢ÀÚ²¿¸®(Ãæ¼ö)ÀÇ ±Þ¼º¿°ÁõÀ¸·Î¼, º¸Åë ÇϺ¹ºÎÀÇ ¿À¸¥ÂÊ 1/4 ºÎÀ§¿¡¼ÀÇ ÅëÁõÀÌ Æ¯Â¡À̸ç, ±¹¼Ò¾ÐÅë, ±ÙÀ°±äÀå ÇǺΰ¨°¢ÀÇ °ú¹Î µîÀ» ¼ö¹ÝÇÑ´Ù. ÀϹݵòµéÀÌ ¡°¸ÍÀå¿°¡±À̶ó°í ÇÏ´Â °ÍÀ¸·Î ¸ÍÀå¿°Àº ¸·Ã¢ÀÚÀÇ ¿°ÁõÀ¸·Î ±¸º°µÇ¾î¾ß ÇÑ´Ù. ¹ß¿°ú ´ÙÇü¹éÇ÷±¸Áõ´Ù´Â ±¹¼Ò°¨¿°ÀÇ °á°úÀÌ´Ù. ¸·Ã¢ÀÚ²¿¸®ÀÇ À§Ä¡-À¯Âø»óÅÂ-²¿ÀÓ µî¿¡ ÀÇÇØ Áõ»ó°ú ¡ÈÄ´Â º¯µ¿µÈ´Ù. |
||
| AML | Acute Myelogenous Leukemia Morphologic Classification(FABºÐ·ù) &n... |
|---|---|
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
| AML | acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem... |
| AP | accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p... |
| SMCA | smooth muscle contracting agent; suckling mouse cataract agent |
| DUE | DNA unwinding element |
|---|---|
| DUE | Drug usage evaluation |
| NV | Norwalk virus |
| NLV | Norwalk-like virus |
| a | Agent |
acute angle
acute arthritis
acute monocytic leukemia
| Norwalk agent | A strain of epidemic gastroenteritis virus that appears to be related to the calciviruses. Origin: Norwalk, Ohio, where first implicated in disease (05 Mar 2000) |
|---|---|
| gastroenteropathy | Any disorder of the alimentary canal. Origin: Gastro-+ G. Enteron, intestine, + pathos, suffering (05 Mar 2000) |
| Norwalk virus | <virology> Unclassified single stranded RNA virus causing common acute infectious gastroenteritis. (18 Nov 1997) |
| due date | The estimated calendar date when a baby will be born, the date the baby is due to be born. It is also called the estimated date of confinement (EDC). (12 Dec 1998) |
| dystonia, focal, due to blepharospasm | The second most common focal dystonia, the involuntary, forcible closure of the eyelids. The first symptoms may be uncontrollable blinking. Only one eye may be affected initially, but eventually both eyes are usually involved. The spasms may leave the eyelids completely closed causing functional blindness even though the eyes and vision are normal. (12 Dec 1998) |
| dystonia, focal, due to torticollis | Spasmodic torticollis, or torticollis, is the most common of the focal dystonias. In torticollis, the muscles in the neck that control the position of the head are affected, causing the head to twist and turn to one side. In addition, the head may be pulled forward or backward. (12 Dec 1998) |
| thrombotic disease due to protein c deficiency | Protein C is a protein in plasma that enters into the cascade of biochemical events leading to the formation of a clot. Deficiency of protein c results in thrombotic (clotting) disease and excess platelets with recurrent thrombophlebitis (inflammation of the vein that occurs when a clot forms). The clot can break loose and travel through the blood stream (thromboembolism) to the lungs causing a pulmonary embolism, brain causing a stroke (cerebrovascular accident), heart causing an early heart attack, skin causing what in the newborn is called neonatal purpura fulminans, the adrenal gland causing haemorrhage with abdominal pain, abnormally low blood pressure (hypotension), and salt loss. Protein c deficiency is due to possession of one gene (heterozygosity) in chromosome band 2q13-14. The possession of two such genes (homozygosity) is usually lethal. (12 Dec 1998) |
| adrenergic blocking agent | A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's. (05 Mar 2000) |
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
| agent | <pharmacology> Any power, principle or substance capable of producing an effect, whether physical, chemical or biological. Origin: L. Agens = acting (18 Nov 1997) |
| agent, antihypertensive | As the name suggests, a drug aimed at reducing high blood pressure (hypertension). (12 Dec 1998) |
| agent, anti-infective | Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright. (12 Dec 1998) |
| Agent Orange | An herbicide and defoliant, consisting of (2,4,5-trichlorophenoxy)acetic acid, (2,4-dichlorophenoxy)acetic acid, and dioxin, that was widely used in the Vietnam War; it has been shown to possess residual post-exposure carcinogenic and teratogenic properties in humans. (05 Mar 2000) |
| agent, tocolytic | A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so let the foetus gain in size and maturity before being born. (12 Dec 1998) |
| alkylating agent | <oncology, pharmacology> A reagent that places an alkyl group, for example propyl in place of a nucleophilic group in a molecule. Alkylating reagents include a number of cytotoxic drugs some of which react fairly specifically with N7 of the purine ring and lead to depurination of DNA, for example the agent ethyl ethanesulphonic acid and thus to mutagenesis. The drugs interaction with DNAand prevents the division of the cells. Examples of drugs include: busulphan, chlorambucil, cyclophosphamide, melphalan. (29 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|